Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jun;61(6):789–794. doi: 10.1038/bjc.1990.178

Dose intensity in cancer chemotherapy.

D J Dodwell 1, H Gurney 1, N Thatcher 1
PMCID: PMC1971684  PMID: 2164831

Full text

PDF
789

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage J. O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood. 1989 May 15;73(7):1749–1758. [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P., Rossi A., Tancini G., Brambilla C., Zambetti M., Veronesi U. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985;5(2):95–115. doi: 10.1007/BF01805984. [DOI] [PubMed] [Google Scholar]
  3. Bronchud M. H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989 Jul;60(1):121–125. doi: 10.1038/bjc.1989.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bruce W. R., Meeker B. E., Valeriote F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst. 1966 Aug;37(2):233–245. [PubMed] [Google Scholar]
  5. Bull J. M., Tormey D. C., Li S. H., Carbone P. P., Falkson G., Blom J., Perlin E., Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649–1657. doi: 10.1002/1097-0142(197805)41:5<1649::aid-cncr2820410501>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  6. Carde P., MacKintosh F. R., Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983 Feb;1(2):146–153. doi: 10.1200/JCO.1983.1.2.146. [DOI] [PubMed] [Google Scholar]
  7. Cohen M. H., Creaven P. J., Fossieck B. E., Jr, Broder L. E., Selawry O. S., Johnston A. V., Williams C. L., Minna J. D. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep. 1977 May-Jun;61(3):349–354. [PubMed] [Google Scholar]
  8. Cooper R. G., Holland J. F., Glidewell O. Adjuvant chemotherapy of breast cancer. Cancer. 1979 Sep;44(3):793–798. doi: 10.1002/1097-0142(197909)44:3<793::aid-cncr2820440302>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  9. Coppin C. M. The description of chemotherapy delivery: options and pitfalls. Semin Oncol. 1987 Dec;14(4 Suppl 4):34–42. [PubMed] [Google Scholar]
  10. Figueredo A. T., Hryniuk W. M., Strautmanis I., Frank G., Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol. 1985 Jan;3(1):54–64. doi: 10.1200/JCO.1985.3.1.54. [DOI] [PubMed] [Google Scholar]
  11. Gulati S. C., Shank B., Black P., Yopp J., Koziner B., Straus D., Filippa D., Kempin S., Castro-Malaspina H., Cunningham I. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol. 1988 Aug;6(8):1303–1313. doi: 10.1200/JCO.1988.6.8.1303. [DOI] [PubMed] [Google Scholar]
  12. Henderson I. C., Hayes D. F., Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988 Sep;6(9):1501–1515. doi: 10.1200/JCO.1988.6.9.1501. [DOI] [PubMed] [Google Scholar]
  13. Hortobagyi G. N., Bodey G. P., Buzdar A. U., Frye D., Legha S. S., Malik R., Smith T. L., Blumenschein G. R., Yap H. Y., Rodriguez V. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar;5(3):354–364. doi: 10.1200/JCO.1987.5.3.354. [DOI] [PubMed] [Google Scholar]
  14. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  15. Hryniuk W., Levine M. N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986 Aug;4(8):1162–1170. doi: 10.1200/JCO.1986.4.8.1162. [DOI] [PubMed] [Google Scholar]
  16. Jagannath S., Armitage J. O., Dicke K. A., Tucker S. L., Velasquez W. S., Smith K., Vaughan W. P., Kessinger A., Horwitz L. J., Hagemeister F. B. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb;7(2):179–185. doi: 10.1200/JCO.1989.7.2.179. [DOI] [PubMed] [Google Scholar]
  17. Jones R. B., Holland J. F., Bhardwaj S., Norton L., Wilfinger C., Strashun A. A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol. 1987 Feb;5(2):172–177. doi: 10.1200/JCO.1987.5.2.172. [DOI] [PubMed] [Google Scholar]
  18. Klastersky J., Sculier J. P., Ravez P., Libert P., Michel J., Vandermoten G., Rocmans P., Bonduelle Y., Mairesse M., Michiels T. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol. 1986 Dec;4(12):1780–1786. doi: 10.1200/JCO.1986.4.12.1780. [DOI] [PubMed] [Google Scholar]
  19. Lagarde P., Bonichon F., Eghbali H., de Mascarel I., Chauvergne J., Hoerni B. Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease. Br J Cancer. 1989 Apr;59(4):645–649. doi: 10.1038/bjc.1989.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 1987 May;5(5):756–767. doi: 10.1200/JCO.1987.5.5.756. [DOI] [PubMed] [Google Scholar]
  21. Ozols R. F., Ihde D. C., Linehan W. M., Jacob J., Ostchega Y., Young R. C. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988 Jun;6(6):1031–1040. doi: 10.1200/JCO.1988.6.6.1031. [DOI] [PubMed] [Google Scholar]
  22. Palmer M., Belch A., Hanson J., Brox L. Dose intensity analysis of melphalan and prednisone in multiple myeloma. J Natl Cancer Inst. 1988 May 18;80(6):414–418. doi: 10.1093/jnci/80.6.414. [DOI] [PubMed] [Google Scholar]
  23. Pinkel D., Hernandez K., Borella L., Holton C., Aur R., Samoy G., Pratt C. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. 1971 Feb;27(2):247–256. doi: 10.1002/1097-0142(197102)27:2<247::aid-cncr2820270202>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  24. Redmond C., Fisher B., Wieand H. S. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep. 1983 Jun;67(6):519–526. [PubMed] [Google Scholar]
  25. Samson M. K., Rivkin S. E., Jones S. E., Costanzi J. J., LoBuglio A. F., Stephens R. L., Gehan E. A., Cummings G. D. Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer. 1984 Mar 1;53(5):1029–1035. doi: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  26. Schabel F. M., Jr, Griswold D. P., Jr, Corbett T. H., Laster W. R., Jr Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer. 1984 Sep 15;54(6 Suppl):1160–1167. doi: 10.1002/1097-0142(19840915)54:1+<1160::aid-cncr2820541312>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  27. Slevin M. L., Clark P. I., Joel S. P., Malik S., Osborne R. J., Gregory W. M., Lowe D. G., Reznek R. H., Wrigley P. F. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol. 1989 Sep;7(9):1333–1340. doi: 10.1200/JCO.1989.7.9.1333. [DOI] [PubMed] [Google Scholar]
  28. Tannock I. F., Boyd N. F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D., Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377–1387. doi: 10.1200/JCO.1988.6.9.1377. [DOI] [PubMed] [Google Scholar]
  29. Valdivieso M., Burgess M. A., Ewer M. S., Mackay B., Wallace S., Benjamin R. S., Ali M. K., Bodey G. P., Freireich E. J. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol. 1984 Mar;2(3):207–214. doi: 10.1200/JCO.1984.2.3.207. [DOI] [PubMed] [Google Scholar]
  30. Van Eys J., Berry D., Crist W., Doering E., Fernbach D., Pullen J., Shuster J. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A Pediatric Oncology Group Study. Cancer. 1989 Apr 15;63(8):1466–1471. doi: 10.1002/1097-0142(19890415)63:8<1466::aid-cncr2820630803>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  31. Wolff S. N., Birch R., Sarma P., Greco F. A. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986 May;70(5):583–587. [PubMed] [Google Scholar]
  32. Woods R. L., Fox R. M., Tattersall M. H. Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation. Br Med J (Clin Res Ed) 1981 Feb 21;282(6264):600–602. doi: 10.1136/bmj.282.6264.600. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES